[Ip-health] UNITAID CONTINUES FUNDING FOR MEDICINES PATENT POOL AND PAEDIATRIC AIDS MEDICINES

Bagozzi, Daniela bagozzid at who.int
Thu Dec 15 04:04:23 PST 2011


 
UNITAID CONTINUES FUNDING FOR MEDICINES PATENT POOL AND PAEDIATRIC AIDS
MEDICINES

Additional US$ 50 Million Allotted to Malaria

Geneva, 14 December 2011 - At its meeting in Paris on 12-13 December,
the UNITAID Executive Board demonstrated its continued commitment to
scaling up access for HIV/AIDS and malaria by allocating an extra US$
138 million to the two diseases. 

UNITAID will provide funding support over the next four years for the
Medicines Patent Pool to negotiate voluntary licences from brand
companies to generic manufacturers to facilitate affordable access to
HIV/AIDS medicines in developing countries.

"Precisely because funding for AIDS is threatened by the economic
crisis, we need to leverage all the tools at our disposal to ensure
staunch commitment to increase treatment coverage," said Philippe
Douste-Blazy, Chairman of the UNITAID Executive Board.  "Innovative
mechanisms that can increase treatment availability and decrease prices,
such as the Pool, are critical components of UNITAID's strategy to
address the funding gap".

The Board resolution on this issue reiterates UNITAID's position that
the Pool should seek a broad geographical scope to include low- and
middle-income countries as potential beneficiaries of the licenses. 

"Because the Pool is a voluntary mechanism, its ultimate success depends
on the willingness of patent holders to share their technology in ways
that allow as many people in developing countries as possible to
benefit," added Philippe Douste-Blazy.  "The Pool has achieved promising
results in its first year and we urge all pharmaceutical companies to
enter into licensing agreements to breach the gap of 15 million people
who need treatment."

The UNITAID Board also committed US$ 62 million to continue supporting
the scale-up of HIV/AIDS treatment for children in partnership with the
Clinton Health Access Initiative. The partnership, which covers about
85% of paediatric AIDS treatment, has been successful in promoting
child-friendly medicines by ensuring long-term, high-volume drug
purchases which have reduced the cost of the medicines by as much as
80%. 

An additional US$ 50 million were committed to the Global Fund to
increase access to artemisinin-based combination therapy (the best known
treatment for malaria today) in the eight African countries that bear
the largest malaria burden.

Contact: Daniela Bagozzi, Tel. +41 22 791 45 44; Mob. +41 79 475 54 90;
Email bagozzid at who.int





More information about the Ip-health mailing list